In July, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider an application from Novartis for Everolimus/Afinitor to be listed on the Pharmaceutical Benefits Scheme (PBS) for people with TSC who are experiencing seizures that do not respond well to available treatments. If the medicine is approved for listing it will be funded by the Australian government as a part of the PBS.
Tuberous Sclerosis Australia will make a submission on behalf of our members and the wider Australian TSC community. We need your input to ensure that the PBAC receives the best information to help them make this decision.
The survey takes between five and ten minutes to complete. The survey will remain open until Saturday 20 May.
For more information, please email email@example.com or call 1300 733 435.